Targeting a specific protein in certain types of uterine cancer
Targeting WEE1 in uterine serous or p53-mutated uterine cancer
This study is looking at a type of uterine cancer that can be hard to treat, and it’s testing a new approach that targets a specific protein to see if it can help improve treatment options for patients like you.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11070304 on NIH RePORTER |
What this research studies
This research focuses on uterine serous carcinomas and p53-mutated uterine cancers, which are known for their poor prognosis and limited treatment options. The study aims to explore the effectiveness of inhibiting the WEE1 protein, which may help these cancers that often exhibit cell cycle dysregulation and high replication stress. By analyzing the response to WEE1-targeting agents, the research seeks to identify potential new therapies that could improve patient outcomes. Patients may be involved in clinical trials assessing the safety and efficacy of these targeted treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with uterine serous carcinoma or p53-mutated uterine cancer.
Not a fit: Patients with other types of uterine cancer or those who do not have p53 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with aggressive forms of uterine cancer.
How similar studies have performed: Previous clinical trials targeting WEE1 in similar cancers have shown promising results, indicating potential for success in this approach.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Liu, Joyce — Dana-Farber Cancer Inst
- Study coordinator: Liu, Joyce
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.